MBX Biosciences, Inc. (NYSE:MBX – Get Free Report) shot up 6.8% on Tuesday . The company traded as high as $21.90 and last traded at $21.22. 63,611 shares changed hands during trading, a decline of 54% from the average session volume of 136,916 shares. The stock had previously closed at $19.86.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on MBX. Stifel Nicolaus began coverage on MBX Biosciences in a report on Tuesday, October 8th. They set a “buy” rating and a $40.00 price target for the company. Jefferies Financial Group started coverage on MBX Biosciences in a report on Tuesday, October 8th. They set a “buy” rating and a $35.00 target price for the company. Guggenheim started coverage on MBX Biosciences in a report on Tuesday, October 8th. They set a “buy” rating and a $44.00 target price for the company. Finally, JPMorgan Chase & Co. started coverage on MBX Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $30.00 price objective for the company.
View Our Latest Research Report on MBX
MBX Biosciences Stock Performance
Insider Transactions at MBX Biosciences
About MBX Biosciences
MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.
Featured Articles
- Five stocks we like better than MBX Biosciences
- How to Use the MarketBeat Dividend Calculator
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- Investing in Construction Stocks
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.